Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been assigned an average rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.6250.

Several equities analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX opened at $2.99 on Friday. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16. The business’s 50-day moving average price is $3.24 and its two-hundred day moving average price is $3.91.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. On average, sell-side analysts predict that Perspective Therapeutics will post -1.1 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CATX. Aigen Investment Management LP acquired a new position in Perspective Therapeutics during the fourth quarter valued at approximately $28,000. Russell Investments Group Ltd. boosted its holdings in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the period. nVerses Capital LLC acquired a new position in Perspective Therapeutics in the 4th quarter valued at $31,000. AXQ Capital LP grew its stake in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after buying an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics in the 4th quarter worth $35,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.